Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Wed, 26.07.2023
Formycon AG
Press release // July 26, 2023
Formycon reports on the regular Annual General Meeting
Shareholders approve all agenda items
Management board and supervisory board ratified by large majority
Wolfgang Essler elected as a new member to the supervisory board
Comprehensive reporting by the management on company development
Munich - On July 25, 2023 [ … ]
Thu, 29.06.2023
Formycon AG
Press Release // June 29, 2023
Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (“Klinge“) announce that the biologics lic [ … ]
Thu, 29.06.2023
Formycon AG
Press Release // June 29, 2023
Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (“Klinge“) announce that the biologics lic [ … ]
Tue, 30.05.2023
Formycon AG
Press Release // May 30, 2023
Formycon reports results for the first quarter 2023
Group revenues amount to Euro 21.5 million (Q1/2022: Euro 8.1 million) and include, in addition to a significant milestone payment for the successful global partnering of FYB202, revenue contributions from the commercialization of FYB201
Group EBITDA of Euro 4.5 m [ … ]
Tue, 30.05.2023
Formycon AG
Press Release // May 30, 2023
Formycon reports results for the first quarter 2023
Group revenues amount to Euro 21.5 million (Q1/2022: Euro 8.1 million) and include, in addition to a significant milestone payment for the successful global partnering of FYB202, revenue contributions from the commercialization of FYB201
Group EBITDA of Euro 4.5 m [ … ]
Wed, 10.05.2023
Formycon AG
Press Release // May 10, 2023
Formycon Announces Participation in International Investor Conferences in Q2/2023
Munich/Martinsried – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that members of the Management Board will present at the following investor conferences in the second quarter of 2023:
Equity Forum – Spring Conference [ … ]
Wed, 10.05.2023
Formycon AG
Press Release // May 10, 2023
Formycon Announces Participation in International Investor Conferences in Q2/2023
Munich/Martinsried – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that members of the Management Board will present at the following investor conferences in the second quarter of 2023:
Equity Forum – Spring Conference [ … ]
Thu, 27.04.2023
Formycon AG
Press Release // April 27, 2023
Formycon publishes results for financial year 2022
Approval and commercial launch of FYB201 as well as ATHOS transaction mark transformative fiscal year
Group revenues increase to Euro 42.5 million (2021 IFRS: Euro 36.6 million) and include first earning contributions from commercialization of FYB201
EBITDA of Eu [ … ]
Thu, 27.04.2023
Formycon AG
Press Release // April 27, 2023
Formycon publishes results for financial year 2022
Approval and commercial launch of FYB201 as well as ATHOS transaction mark transformative fiscal year
Group revenues increase to Euro 42.5 million (2021 IFRS: Euro 36.6 million) and include first earning contributions from commercialization of FYB201
EBITDA of Eu [ … ]
Tue, 25.04.2023
Formycon AG
Press Release // April 25, 2023
Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Positive data from extended Phase I pharmacokinetics study complete clinical development program
Phase I and phase III clinical trial program demonstrated comparable safety [ … ]